Managing Peri-Implantitis and Peri-Mucositis with Direct Medication Delivery

Duane Keller*, Marissa Buechel

Keller Professional Group PC, Perio Protect LLC, Bayless Avenue, St. Louis, MO, USA
*Corresponding Author: Duane Keller, Keller Professional Group PC, Perio Protect LLC, Bayless Avenue, St. Louis, MO, USA. E-mail: drdkeller@sbcglobal.net

Citation: Duane Keller et al. (2017), Managing Peri-Implantitis and Peri-Mucositis with Direct Medication Delivery. Int J Dent & Oral Heal. 3:10, 116-127 DOI: 10.25141/2471-657X-2017-10.0103

Copyright: ©2017 Duane Keller et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

Received: November 25, 2017; Accepted: December 05, 2017; Published: December 30, 2017

Abstract

Background: Periodontal disease and peri-implantitis/perimucositis are a host inflammatory response to the biofilm in the gingival sulcus or periodontal pocket. Some patients with a propensity for gum disease may not respond to mechanical treatments like scaling / root planing and surgery as the treatments leave the bacteria that caused the disease in the gingival tissue, on the surface of the roots of the tooth or implant. Mechanical treatments may foster biofilm regeneration, introduce the bacteria, toxins and host inflammatory products into the systemic circulation resulting in an increased incidence of bacteremia. This three part study demonstrates effective biofilm control using a direct medication delivery method by three different practitioners for three different patients.

Method: Direct medication delivery uses hydrogen peroxide gel (Perio Gel) and a sub-clinical dose of doxycycline (Vibramycin, Pfizer) delivered subgingival and interproximal using custom formed medical devices (Perio Tray [Perio Protect LLC St. Louis, MO.]). Hydrogen peroxide forms oxygen that approaches hyperbaric oxygen when generated within the Perio Tray. The method was used in accordance with the patient's conditions and the treatments were modified as healing occurred. Direct medication was used first to control the biofilm and debride the wound and mechanical means to remove biofilm deposits were used where needed. Three cases are presented to demonstrate efficacy, bacterial changes and clinical and radiographic improvements with treatment.

Results: Use of direct medication delivery demonstrated a resolution of peri-implantitis/mucositis and periodontal disease with decreased pocket probing depth and bleeding upon probing. A pre-treatment salivary DNA analysis showed a pathogenic biofilm constituency compared to a post-treatment salivary analysis showing a less virulent population. Implants with bone loss were shown to increase threads coverage with direct medication delivery. Pathogen specific DNA analysis before, during and after treatment demonstrated a significant decrease in the virulence and the number of bacteria demonstrating an ability to modify the cause of disease and managing the cause over time.

Conclusion: Direct medication delivery of hydrogen peroxide gel and doxycycline using custom formed medical devices were effective in treating periodontal disease, peri-implantitis and perimucositis. Direct medication delivery demonstrated a significant modification in the biofilm by decreasing number and virulence of bacteria, improved tissue responses and decreased pocket probing depth and bleeding upon probing. An implant that suffered bone loss was treated by direct medication delivery and the bone loss was reversed as exposed implant threads were recovered by new bone.

Keywords: Biofilm, Peri-implantitis / Perimucositis, Direct Medication delivery, Perio Protect Method, Perio tray, Perio gel, Bone Reformation
Introduction

Treatment of periodontal disease is important as the World Health Organization Report of 2003 and 2006 shows between 85 to 90% of people worldwide have some form of periodontal disease. The American Academy of Periodontology, when citing a Center for Disease Control study, state that almost 50% of Americans have moderate to severe periodontal disease which increases with age. The bacteria responsible for periodontal disease are part of the cause of peri-implantitis and perimucositis, and effectively treating the cause of periodontal disease, peri-implantitis and perimucositis is important. These same bacteria are also related to systemic disease, such as cardiovascular disease, pregnancy complications, arthritis, Alzheimer’s disease and other systemic inflammatory dysfunctions. The biofilm control for peri-implant disease has emerged as an ever increasing problem as the number of implants to replace missing teeth has increased and the prevalence of mucositis was evident in 80% of the subjects and in 50% of the implants. These same authors reported peri-implantitis existed in 28% to 56% of the patients involving 12% to 48% of the implants.

Successful biofilm control for periodontal disease and perimucositis / peri-implantitis disease must coincide with guidelines for similar chronic inflammatory wounds. Wound Care Guidelines by the Wound Healing Society delineate specific steps for the medical community in wound management. The steps include: diagnosis, infection control, wound bed preparation, wound care management, long-term management and prevention. These same steps in medical treatment are applied for both acute and chronic wounds in dental treatments with direct medication delivery when used for periodontal disease, peri-implantitis and perimucositis.

Wounds are usually classified as either acute or chronic. Acute wounds which are predominantly caused by planktonic bacteria can be treated with antibiotics. Antibiotics are less effective against chronic wounds. Most chronic wounds like periodontal disease are caused by micro-organisms that live in a biofilm and the nature of the biofilm makes it more difficult to manage when compared to planktonic bacteria. Antimicrobial wound management involving biofilm control requires the ability of the medication to penetrate the biofilm matrix with sufficient effectiveness to modify the microenvironment in order to alter the biofilm. The biofilm is seldom completely eradicated during treatment and the biofilm continues to regrow, resulting in a need for medication re-application.

Medical wound care guidelines for biofilm infections recommend the use of topically applied antimicrobials in place of antibiotics prior to wound debridement. Hydrogen peroxide gel is an antimicrobial wound debridement agent that follows medical guidelines in chronic wound management as it begins the infection control and debridement when delivered with a direct medication method. The ability to reapply the medication through direct medication delivery is an infection control mechanism that can be part of treatment as well as long-term wound management. Long term care involves using directed medications on a prescribed basis guided to the cause of the infection as part of a prevention technique.

The biofilm invasion and persistence in the gingival tissue results in a chronic inflammation related to host risk factors as components of pathogenicity. Treating the subgingival biofilm reduces host responses in both periodontal disease and implant infections. Comparison of host responses involved evaluating bacteria associated with peri-implantitis compared with periodontitis pathogens. The biofilm in peri-implantitis was more complex than periodontitis as the primary bacteria were Gram-negative obligate anaerobes, but peri-implantitis demonstrated a differing prevalence to periodontitis. Other researchers found higher levels of periodontal pathogenic bacteria comparing peri-implantitis patients with healthy stable implants. These pathogens colonize the sub-gingival crevice soon after implant placement, as the biofilm community becomes organized resulting in inflammation of the supporting bone and related tissue injury.

Current methods of treatment and prevention involve individual oral hygiene instructions and professional mechanical plaque (biofilm) removal along with behavioral interventions to decrease risk factors and augment periodontal prevention. Problems are reported for methods using mechanical removal of plaque and biofilm components. Mechanical treatments show a significant decrease in the initial number of biofilm members, but biofilms regrow to exceed pre-treatment levels within 2 to 7 days on natural and denture teeth.

Complications exist for other treatments focusing on the control of infection on implants involve the detoxification of the implant surface and regeneration of the alveolar bone as a means to control the disease and host response. Surgical treatment of peri-implantitis at six months showed most sites continued to have bleeding on probing and/or suppuration, leading the authors to recommend better long-term maintenance options. Bacteremia occurs with mechanical interventions such as scaling and root planing and/or surgery through an increased incidence of bacteria, bacterial toxins or host inflammatory products becoming systemically dispersed.

Mechanical intervention such as scaling and root planing (S&RP) leaves the same biofilm agents in the subgingival region following treatment that were there prior to S&RP. It is only a matter of time before the bacteria regenerate as investigations have shown that mechanical debridement causes a three to four fold increase in biofilm reproduction. Any increase in biofilm regeneration is detrimental to wound healing. Homecare may not be able to reach subgingival biofilms around many implants and homecare can be a contributing factor to bacteremia. The remaining bacteria regrow and research has shown the subgingival biofilm recolonization is extremely diverse.

In attempting to manage the biofilm regeneration, adjunctive
peri-implant therapies, such as antibiotics, antiseptics, and ultrasonic and laser treatments, have been proposed to improve the treatment options of peri-implant mucositis and peri-implantitis. However, evidence suggests these methods may not be sufficient and results may be similar to conventional debridement\textsuperscript{38-41}.

Comparing results of open flap debridement of peri-implantitis with and without adjunctive systemic antibiotics demonstrated there was no significant difference in benefits with using the antibiotics\textsuperscript{42}. The criteria for success in this study was also pocket probing depths of < 5mm which provides an environment where facultative and obligate anaerobes may become the predominant species\textsuperscript{43,44}.

Reports of sub-mucosal debridement accomplished by utilizing either an ultrasonic device or carbon fiber curettes demonstrate these are not sufficient for the decontamination of the surfaces of implants with peri-implant pockets \(\geq 5\) mm and exposed implant threads\textsuperscript{45}. Application of topical antiseptics like 2% Chlorhexidine has resulted in changes in the topical biofilm\textsuperscript{46} and Chlorhexidine may adversely affect the host inflammatory response. Chlorhexidine causes an increase in inflammatory chemokines and cytokines and inhibit gingival fibroblast activity\textsuperscript{47}. Chlorhexidine increases poor cellular morphology, increases the reactive oxygen species per unit area and greatly diminishes the number and vitality of osteoblasts in a concentration-dependent manner\textsuperscript{48}.

Research on the use of lasers shows the efficacy of Er:YAG laser appeared to be limited to a 6-month period and the treatment with Er:YAG laser may not be adequate for stable long-term therapeutic measures\textsuperscript{49}. Research of conventional nonsurgical therapy even with the use of adjunctive systemic and local antibiotic are minimally effective and surgical intervention failed to demonstrate re-osseous integration\textsuperscript{50}. Conventional treatments are not able to manage the biofilm cause of peri-implantitis in correction of defects around implants\textsuperscript{51}.

In light of these problems in treating periodontal disease, peri-implantitis and perimucositis infections, a direct medication delivery system (Perio Protect Method, St. Louis, MO) was used to evaluate the management of the causative agents and host responses around implants. The direct medication delivery system (Perio Protect Method) uses custom formed medical devices (Perio Tray) to deliver hydrogen peroxide gel (1.7%) [Perio Gel], with or without doxycycline, to modify the micro-environment of the gingival sulcus and tissues around teeth resulting in decreased tissue inflammation, decreased pocket depth and diminished bleeding upon probing\textsuperscript{52}. Prior studies on natural teeth using medications delivered by this subgingival deliver method increased the oxygen saturation to 5.7 X which is comparable to hyperbaric oxygen and the medicaments are delivered up to 9mm subgingival and were maintained for over 15 minutes\textsuperscript{53}.

Research using a live/dead dye demonstrated that virtually 100% of the surface biofilm bacteria were eradicated in 15 minutes. Other studies of this method demonstrated 98% to 100% of the biofilm micro-organisms were eradicated by using the hydrogen peroxide gel when applied and subsequently reapplied directly to the biofilm\textsuperscript{54}. The delivery, maintenance and ability to reapply medications enable better control of the etiology of infection.

The direct medicine delivery device (Perio Tray) through the formation of oxygen under pressure (hyperbaric oxygen) facilitates wound healing through a number of positive healing processes such as angiogenesis, fibroblast proliferation, leukocyte oxidative killing, toxin inhibition and antibiotic synergy\textsuperscript{55}. Hyperbaric oxygen increases fibroblastic proliferation and leads to increased neovascularization\textsuperscript{56}. Hyperbaric oxygen reverses vasoconstrictive hypoxia and reduces tissue edema and tissue swelling\textsuperscript{57}. Oxygen is vital for hydroxylation of lysine and proline as part of collagen synthesis for improved cross linking thus increasing the collagen strength required for strong wound healing\textsuperscript{58}. Wound healing with hyperbaric oxygen has demonstrated significant healing rates in 87% of patients when dealing with non-traumatic wounds\textsuperscript{59} and hyperbaric oxygen is an instrumental aspect of non-healing wound care with the medical profession\textsuperscript{60,61}.

Delivery of hydrogen peroxide and doxycycline has been shown to inhibit osteoclasts through hyperbaric oxygen generation and doxycycline augments osteoblastic activity\textsuperscript{62}. This helps explain how direct medication delivery of hyperbaric oxygen and doxycycline to the periodontal pocket has resulted in decreased bone loss and increased bone apposition around natural teeth\textsuperscript{63}. Direct medication delivery was demonstrated to control the biofilm responsible for causing periodontal disease\textsuperscript{64} and resulted in improved patient conditions\textsuperscript{65}. These studies found changes from a community of predominant virulent microorganisms to a post-treatment community of a less virulent population and the number of bacteria decreased by a - log 2-4. Since there is a correlation between the etiology of periodontal disease and peri-implantitis / perimucositis, the method that was effective around natural teeth is used in this study to evaluate efficacy around implants.

\textbf{Method and Protocol:}  
Direct medication delivery (Perio Protect Method) delivers hydrogen peroxide (Perio Gel 1.7%) used in combination with doxycycline into the gingival sulcus or periodontal pocket and the frequency of treatment is determined by the patient’s conditions (pocket probing depth and bleeding indices). The severity of the patient’s disease at the onset of treatment determines the initial frequency of treatment. The direct medication delivery method advocates wearing the trays for 15 minutes 1-4 times / day so the medications (hydrogen peroxide, hyperbaric oxygen and Vibramycin [doxycycline [Pfizer] 50 mg/5ml]) can control or modify the biofilm etiology of disease. The treatment progress is determined by the patient pocket probing depth changes and changes in the bleeding indices as treatments are modified in accordance with improvements in the pocket probing depths and bleeding indices (Figure 1).
Direct medication delivery protocol

- 7mm pockets or >                           4 times / day @ 15 minutes
- 3-6mm pockets                              3 times / day @ 15 minutes
- <3mm pockets                               2 times / day @ 15 minutes
- Maintenance                                1-2 times / day @ 15 minutes

Patients with severe conditions (6mm or >) = 2 / day
Patients with 5mm or less = 1 / day

Figure 1 The time and frequency of treatments with direct medication delivery are determined by the patient’s conditions. The patient’s initial pocket probing depths are recorded and the most severe conditions determine the frequency of treatment in accordance with the guidelines provided. The treatments are modified as healing occurs and patient’s conditions improve. Long-term maintenance is advocated in accordance with the initial patient conditions to prevent reoccurrence of the disease and improved host response.

The Perio Tray serve to increase the oxygen saturation within the tray to 5.7 X atmospheres. The formation of oxygen under pressure (hyperbaric oxygen) facilitates wound healing through angiogenesis, fibroblast proliferation, leukocyte oxidative killing, toxin inhibition and antibiotic synergy. Hyperbaric oxygen increases neovascularization, reverses vasoconstrictive hypoxia and reduces tissue edema and tissue swelling and oxygen increases the collagen strength required for strong wound healing.

Use of the Perio Tray prior to mechanical intervention facilitates biofilm management through decreasing the number and virulence of the bacteria decreasing the probability of bacteremia.

The action of hydrogen peroxide modifies the calculus, facilitating removal. Adjunctive treatments are part of the direct medication delivery method that may include scaling and root planing to remove subgingival calculus and tarter and laser or conventional surgery where conditions warrant, such as granulomatous tissue. The trays may be worn prior to invasive therapy to control the biofilm before mechanical interventions cause a local inflammatory response or systemic bacteremia. The trays are worn as part of the long-term maintenance after active treatment to provide a micro-environment that controls the pathogens, decreases reoccurrence and augments tissue recovery.

Three cases are used to illustrate the treatment efficacy, biofilm modifications, radiographic and tissue improvements. The first patient with advanced periodontal disease received conventional treatments. The doctor used treatments included scaling and root planing, antibiotic therapy, topical antiseptic rinses, laser and conventional surgery in an attempt to control the infection. The treatments were unsuccessful and three teeth in the patient’s upper right quadrant were extracted and replaced with implants in 2007. Routine maintenance and homecare were implemented to assist the patient in controlling the oral conditions. By 2014 there were 4 to 7mm pockets around the implants with bleeding upon probing and moderate subgingival calculus. Conventional treatments including surgery were discussed, but the patient wanted to avoid more surgery, so other options were proposed. The patient chose to use the Perio Protect Method through direct medication delivery using prescription trays (Perio Tray). Impressions were completed and the custom medical devices were fabricated and treatments were implemented in accordance with the Perio Protect Protocol. (Figure 2)
A salivary diagnostic test was completed (figure 3) prior to treatment to evaluate the bacteria present in the subgingival area. The DNA saliva analysis showed a presence of bacterial biofilm associated with advancing periodontal disease. This analysis was used to compare results with a post-treatment analysis to determine treatment efficacy. Perio Trays were placed in August 2014 in accordance with the pocket probing depth and the bleeding index. The tray usage was four times per day spread over the course of the day for a time of 15 minutes per application.

The initial frequency of Perio Tray usage in August 2014 was 4 times a day as determined by the patient’s initial pocket probing depths. After a few weeks additional treatments also included four rounds of periodontal debridement, laser therapy and subgingival irrigations between September and November 2014. A re-evaluation visit on December 2014 (figure 4) demonstrated a significant decrease in bleeding upon probing and the pocket probing depths decreased where the deepest pocket measured 5mm. This patient continued to use the direct medication delivery system as a part of the Perio Protect maintenance regimen.
Use of a direct medication delivery method (Perio Protect Method) showed significant improvements and disease management. Figure 5 shows an initial DNA analysis (Oral DNA) of bacteria present before direct medication delivery and after direct medication delivery. The bacteria comprising the predominant species before treatment are not the same bacteria found after direct medication delivery. Eight of the eleven bacterial species present before treatment were not discovered post-treatment. Three bacterial species remained, but only one of these was found at a clinically sufficient concentration. These changes demonstrate a change in the species present before and after treatment and also demonstrate a reduction in the number of bacteria related to the direct medication delivery. Use of the direct medication method prior to mechanical or invasive techniques may decrease the possibility of bacteremia from the mechanical treatments as fewer bacteria are evident.

The salivary DNA analysis demonstrated a significant change in the biofilm constituency. The change in the bacteria relate to the host improvements as pocket probing depth and bleeding upon probing decrease. Figure 6 demonstrates the before and after pocket probing depth and bleeding indices around the maxillary teeth and implants before and after direct medication usage as the cause of disease/infection is managed. The frequency of treatments is modified as the patient’s conditions improve until the direct medication delivery is part of the long-term maintenance program.

Figure 5: The initial bacteria present in the saliva in 2014 are evident in the first report. The bacteria found in the saliva after direct medication delivery in 2015 demonstrate that five of the eight bacterial species present in the pre-treatment test were completely eliminated including T. forsythia. This demonstrates a significant reduction in both the type of virulent bacteria and the number of bacteria reported to be responsible for periodontal disease in accordance with accepted wound care guidelines.

The second case evaluates radiographs taken at the time of implant placement, after the development of peri-implantitis and after treatments with direct medication delivery. The implant was placed in 2007 (figure 7). The implant placement was done without problems and tissues at this time were normal without any sign of infection. The top of the implant was positioned even with the alveolar crest so all of the threads of the implant engaged alveolar bone.

Figure 6: The patient’s maxillary conditions (pocket probing depth and bleeding upon probing) before treatment are compared to the after treatment results on the right. Changes in the type and number of bacteria are found to correspond with the patient’s inflammatory improvements. The frequency of custom tray usage is modified as healing occurs. Bleeding upon probing and pocket depths are decreased by direct medication delivery of hydrogen peroxide (Perio Gel 1.7%) and Vibramycin.
Figure 7: The post-implant placement radiograph demonstrated the conditions at the time the implant was placed. The implant and healing cap were placed so all of the implant threads engaged bone. All of the implant threads were surrounded by bone in this slide taken August 2007.

The healing cap was removed and the analog and crown were place in February 2008. The patient returned for a re-evaluation appointment due to swelling, bleeding and pain around the implant by April 2009. During the clinical examination a purulent exudate was discovered and a diagnosis of peri-implantitis was determined. Systemic antibiotics were administered as well as several office visits for mechanical debridement, laser surgery and local irrigation to cleanse the area around the implant. The tissues remained infected, tender and swollen and the bone support around the implant became compromised as four threads were exposed above the alveolar crest. (figure 8).

Figure 8: In April 2009 the patient was aware of an infection with swelling and pain and clinically there was a periodontal pocket and bleeding upon probing. During the clinical examination a purulent exudate was discovered. Systemic antibiotics were administered as well as several office visits to irrigate and cleanse the area around the implant. Mechanical treatments and laser therapy were used, but the infection and defect remained. The implant was now compromised by April 2009 as four threads of the implant are exposed.

Perio Trays were delivered June 16, 2009. The patient’s tissue conditions began to improve within a few days. There was no longer a purulent exudate and the pocket depth decreased as did the bleeding upon probing. After the treatment phase, the patient used the direct medication delivery as part of the long-term maintenance program using Perio Gel (1.7% hydrogen peroxide gel) and local delivery of Vibramycin syrup. The Vibramycin was placed in the Perio Tray and worn for the prescribed treatment time as per the doctor’s instructions.

Subsequent radiographs taken in May of 2012 (figure 9) indicate reformed bone where two of the four threads were covered by new bone and two of the four threads remain above the alveolar crest. This indicates there is a decreased bone loss and an augmentation of bone regeneration. Clinical evaluation in July 2013 demonstrated there was no peri-implantitis or perimucositis as the implant was stable for four years as the patient maintains the health of the tissue with direct medication delivery.
The direct medication delivery method is able to modify the biofilm components as determined by changes in the type and number of bacteria present in the biofilm. The third example involves pre-treatment DNA analysis before implant placement, following implant placement and following restoration of the implant. The initial DNA analysis was completed for tooth #14 prior to removal and replacement with an implant. Figure 10 shows the type and frequency of bacteria through a DNA analysis that were gathered by negative pressure around tooth #14. The DNA analysis showed the biofilm composition prior to treatment for any bacteria present at least 2% of the total number as well as the total number of bacteria per area of the samples (1.18 X 10^5).

A custom formed tray was fabricated in accordance with the patient’s conditions and the wearing sequence was modified as healing occurred. The initial treatment was twice a day for 15 minutes. The medical device was used to control the biofilm prior to implant placement. The tooth was removed and the patient continued to wear a Perio Tray once a day during the healing process. After 6 months the implant was placed subgingival and remained in place for 6 months as the patient continued wearing the Perio Tray once a day. A healing cap was placed on the implant for three months. The Perio Tray was modified during these times for the implant and healing cap. After the placement of the healing cap the maxillary Perio Tray was worn using both Vibramycin and the Perio Gel (hydrogen peroxide 1.7%). Subsequent DNA cultures were taken by the negative pressure method as described (Keller and Buechel). There was a dramatic decrease in both the number and characteristics of the biofilm from the pre-treatment analysis. Figure 11 demonstrates there were not enough bacteria present in any of the three samples to register any bacteria. This demonstrates a significant reduction in both the type and the number of bacteria around the implant and healing cap following direct medication delivery.
Sample submitted for Decodex Level 2 Testing had INCONCLUSIVE results. No further attempts will be made to run this sample.

**Figure 11:** DNA cultures were collected and submitted three times to determine the scope and magnitude of the biofilm around the implant and healing cap. All three cultures had insufficient bacteria for an adequate DNA analysis demonstrating a change in the biofilm. These results demonstrate a negative (-) log4-5 reduction in the number of bacteria around the implant following the direct medication delivery of hydrogen peroxide and Vibramycin to this region. There was an insufficient biofilm to determine predominant species.

An analog and crown were placed over the implant. A new Perio Tray was fabricated for the changed oral conditions. The seal around the implant directed the medications subgingival and interproximal and a culture was taken at two months for DNA bacterial analysis around the crown and implant. The numbers of bacteria around the implant were evaluated and there was a log 1-3 number of bacteria comprising the biofilm. This equates to an overall reduction from the initial culture of a –log 2-4 change in the number of bacteria. The predominant species before treatment was not the same predominant species found after treatment.

**Figure 12:** Following the placement of the analog and crown, the biofilm was re-evaluated and found at a log 101-3 order. The overall reduction in the number of bacteria was a - log -2-4 and the predominant species before treatment was not the same as the predominant species after treatment.

**Results:**
Direct medication delivery reduced pocket probing depths and bleeding upon probing around implants. Salivary analysis of the biofilm following direct medication delivery demonstrated a significant alteration in both the type and the number of bacteria in the biofilm. Radiographic evidence of peri-implantitis bone loss was first halted and then reversed with direct medication delivery of hydrogen peroxide and doxycycline as new bone was evident as threads once exposed were re-supported by newly formed bone. Tissue conditions appear to improve as the biofilm population is modified. Bacterial DNA analysis showed the type and number of bacteria are changed during direct medication treatment. The predominant species before therapy was not the same as the post-treatment predominant species. The sample present before treatment is more numerous and appears to be more virulent than the decreased number and type of post treatment species. This change in the biofilm appears to relate to the improved patient conditions of decreased pocket probing depth and bleeding upon probing. The only adverse side effect was the teeth were whitened by the hydrogen peroxide.

**Conclusion:**
Direct medication delivery guides medications to the source of periodontal disease, peri-implantitis and perimucositis. The medications cause a change in the subgingival biofilm. A DNA analysis of the biofilm demonstrated a significant population of bacteria prior to prescription tray usage (1.18 X 105). Following treatment with direct medication delivery there was a net reduction of a –log 2-4 in the number of bacteria. The before treatment predominant species was not the same as the after treatment species. Direct medication delivery results in reducing the presence of virulent bacteria which are replaced by less virulent bacteria. Direct medication delivery to teeth and implants provides benefits that assist conventional treatments like scaling and root planing, laser surgery and topical antimicrobial rinses. Direct medication delivery helps in wound debridement through disruption of the biofilm. Wound healing is improved by the medicinal effect of hydrogen peroxide and hyperbaric oxygen. The decreased number and type of bacteria may decrease the incidence of bacteremia as more virulent bacteria are replaced by less virulent bacteria. This also helps explain local healing as pocket depths and bleeding upon probing decrease around implant with direct medication delivery. Bone loss is halted and new bone is evident as threads that were once exposed are recovered by new bone around an implant with peri-implantitis. This is due to the osteogenic activity of the medications delivered into the periodontal pocket. Direct medication application is widely applicable due to the incidence of periodontal disease throughout the world. Combining direct medication delivery with conventional methods may help
control the etiology of disease and reinfection through both a treatment program and maintenance and prevention program. This article demonstrates the effectiveness of direct medication delivery for implants and for natural teeth used in combination with conventional methods. There are no ethical concerns found with this method except the side effect of whitening teeth.

**Discussion:**

Periodontal disease, peri-implantitis and perimucositis are worldwide problems that may be helped by direct medication delivery using custom formed medical devices to deliver doctor selected medications subgingival and interproximal to control the etiology of disease. This article demonstrated that for three patients there was a positive response to direct medication delivery of hydrogen peroxide gel and doxycycline syrup to the periodontal pocket around teeth and implants. The custom formed trays hold the medications in place and the medications provide multiple therapeutic benefits, such as providing hyperbaric oxygen, enabling anti-inflammatory benefits and helping to control microorganisms. Managing the bacteria in periodontal pockets and around implants reduces the type and number of bacteria. Reducing the virulence and number of bacteria may provide positive results by decreasing bacteria present for systemic bacteremia. Direct medication delivery is an easy and simple means whereby the doctor can assist the patient in biofilm control. Direct medication delivery also provides distinct advantages when used with conventional mechanical treatments through managing the causes of the disease. This is exemplified by the decreased pocket depth, decreased bleeding upon probing and healing that occurred for the cases shown. Direct medication delivery provides materials like doxycycline to the periodontal pocket that assist in osteogenic control as illustrated by the bone regeneration in response to therapy. The bacteria as determined by DNA analysis showed changes in the biofilm constituency as the predominant species at the onset of treatment were not the same as the bacteria found at the end of treatment. Controlling the biofilm species and number of bacteria resulted in improvements in the host inflammatory conditions around infected implants and teeth where pocket probing depth and bleeding upon probing were managed. Decreasing the bacterial population and virulence provides advantages in health for the patient. Direct medication delivery can be utilized both as a treatment method and long-term management and prevention technique.

This study has a limited population and opinions reached must take this limitation into consideration. A larger study over a greater period of time needs to be completed for additional proof of efficacy. This article demonstrates specifics of treatments that the individual health care provider will need to consider when determining the optimum ways to address a chronic wound like periodontal disease and peri-implantitis and perimucositis.

**Conflict of interest:**

Dr. Duane C Keller is CEO and President of Perio Protect and has a vested interest in the company.

**Authors Contribution:**

Dr Duane Keller 95% drdkeller@sbcglobal.net
Ms. Marissa Buechel 5% mbuechel@drduanekeller.com

**Acknowledgements:**

Dr. Jeffery N Goldstein
Dr. Greg Sawyer

**References**

1. http://www.who.int/oral_health/disease_burden/global/en/
2. https://www.perio.org/consumer/cdc-study.htm
3. Cortelli SC, Cortelli JR, Romeiro RL et al. Frequency of periodontal pathogens in equivalent peri-implant and periodontal clinical statuses. Arch Oral Biol 2013;58(1):67-74
4. Eke PI, Dye BA, Wei O, et al. Prevalence of periodontitis in adults in the United States: 2009 and 2010. JDR Published online August 30, 2012 0022034512457373
5. Leishman SJ, Do HL, Ford PJ. Cardiovascular disease and the role of oral bacteria. J Oral Microbiol 2010;2: 10.3402/jom.v2i0.5784
6. https://www.perio.org/consumer/AAP_EFP_Pregnancy
7. Loyola-Rodriguez JP, Martinez-Martinez RE, Abud-Mendoza C et al. Rheumatoid arthritis and the role of oral bacteria. J Oral Microbiol 2010;2: 10.3402/jom.v2i0.5784
8. Rheumatoid arthritis is linked to oral bacteria: etiological association Mod Rheumatol 2009;19(5):453-6
9. Association between periodontitis and Alzheimer’s disease. Abbayya K, Puthanakar NY, Nadeewinmani S et al. N Am J Med Sci 2015;7(6):241-6
10. Li X, Kolltveit KM, Tronstad L, et al. Systemic diseases caused by oral infection Clin Microbiol Rev 2000;13(4):547-58
11. Valente NA, Andreana S. Peri-implant disease: what we know and what we need to know. J Periodontal Implant Sci. 2016;46(3):136-51
12. Zitzmann N. U. Berglundh T. Definition and prevalence of peri-implant diseases. J Clin Periodontol 2008;35: 286–291,
13. http://woundheal.org/Publications/WHS-Wound-Care-Guidelines.cgi
14. Bjarnsholt T. The role of bacterial biofilms in chronic infections. APMIS Suppl 2013;136:1-51 doi:10.1111/apm.12099
15. Wu H, Moser C Want HZ et al. Strategies for combating bacterial biofilm infections. Int J Oral Sci 2015;7(1):1-7
16. Barbul, A. Clinical Treatment Guidelines, Wound Rep Reg. 2006; 14: 645-711.
17. Ji S, Choi YS, Choi Y. Bacterial invasion and persistence: critical events in the pathogenesis of periodontitis J Periodontal Res 2014;doi:10.1111/jre.12248 [E pub ahead of print]
18. Aruni AW, Dou Y, Mishra A, Fletcher HM. The biofilm community-rebels with a cause. Curr Oral Health Rep 2015;2(1):48-56
19. Yue C, Zhao B, Ren Y et al. The implant infection paradox: why do some succeed when others fail? Opinion and discussion paper. Eur Cell Mater. 2015;29:303-10
20. Koyanagi T Sakamoto M, Takeuchi Y, et al. Comprehensive microbiological findings in peri-implantitis and periodontitis. J
21. Botero JE, Gonzales AM, Mercado RA, et al. Subgingival microbiota in peri-implant mucosa lesions and adjacent teeth in partially edentulous patients J Periodontol 2005;76(9):1490-5

22. Sanz M, Newman MG, Nachmani S, et al. Characterization of the subgingival microbial flora around endosteal sapphire dental implants in partially edentulous patients. Int J Oral Maxillofac Implants 1990; 5, 247–253.

23. Quirynen M, Vogels R, Peeters W, et al. Dynamics of initial subgingival colonization of ‘pristine’ peri-implant pockets. Clin Oral Implants Res 2006;17, 25–37.10.1111/j.1600-0501.2005.01194.x

24. Tonetti MS, Eickholz P, Loos, BG et al. Principles in prevention of periodontal diseases. J Clin Periodontol 2015:42(S16):S5-11

25. https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0090138/ Dental scaling and root planing for periodontal health: a review of the clinical effectiveness, cost-effectiveness and guidelines. Canadian Agency for Drugs and Technologies in Health 2016.

26. Teles, FR, Teles RP, Sachdeo A, et al. Comparison of microbial changes in early re-developing biofilms on natural and denture teeth. J Periodontol 2012;83(9):1139-48

27. Teles FR, Teles RP Uzel NG et al. Early microbial succession in re-developing dental biofilms in periodontal health and disease. J Periodontal Res 2012;47(1):95-104

28. Prathpachandran J, Sureth N. Management of peri-implantitis DRJ 2012;9(5):516-21 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3612185/

29. Koldsland OC, Wohlfahrt JC, Aass AM. Bucal. 2014 Jan; 19(1): e67–e73.

30. Asi KS, Gill AS, Mahajan S. Postoperative bacteremia in periodontal flap surgery, with and without prophylactic antibiotic administration: A comparative study J Indian Soc Periodontol 2010;14(1):18-22

31. Waghmare AS, Vhammane PB, Ruhee BS et al. Bacteremia following scaling and root planing: A clinico-microbiological study. J Indian Soc Periodontol 2013;17(6):725-30

32. Resposo S, Tobler J, Alfant B, et al. Differences between biofilm growth before and after periodontal therapy. J Dent Res 2010;99(11):2030-7

33. Palmer, RJ, Caldwell DE. Effects of mechanical dental therapy J Micro Methods 1995;24(2):171-82

34. Schultz G, Bjarnsholt T, James G, et al. Consensus guidelines for the identification and treatment of biofilms in chronic non-healing wounds. Wound Repair and Regen. 2017: doi: 10.1111.wrr.12590

35. Wingrove S. http://www.rdhamag.com/articles/print/volume-33/issue-9/features/focus-on-implant-home-care.html

36. Mang-de la Rosa MR. Castellanos-Cosano L., Romero MJ, Cutando A. The bacteremia of dental origin and its implications in the appearance of bacterial endocarditis. Med Oral Patol Oral Cir Bucal. 2014 Jan; 19(1): e67–e73.
treatment concept cases. A procedure for correcting defects around tilted and horizontal implants. Inside Dent 2017;13(5):40-5

52. Putt M, Mallatt M, Messmann L, Proskin HM. A six month clinical investigation of custom tray application of peroxide gel with and without doxycycline as adjuncts to scaling and root planing for treatment of periodontitis. Am J Dent 2014;27(5):274-84

53. Dunlap T, Keller DC, Marshall MV et al. Subgingival delivery of oral debriding agents: a proof of concept. J Clin Dent. 2011;22(5):149-58

54. Schaudinn C, Gorur A, Sedghizadeh PP et al. Manipulation of the microbial ecology of the periodontal pocket. World Dental 2010;2(1):14-18

55. Bhutani S, Vishwanath G. Hyperbaric oxygen and wound healing. Indian J Plast Surg 2012;45(2):316-24

56. Leach MR, Rees PJ, Wilmshurst P. Hyperbaric oxygen therapy. BMJ 1998;317(7162):1140-43

57. Neuman TS, Thom SR. Physiology and medicine of hyperbaric oxygen therapy. Elsevier Health Science 2008

58. Bhutani S, Vishwanath G. Hyperbaric oxygen and wound healing. Indian J Plast Surg 2012;45(2):316-24

59. Andre-Levigne D, Modarressi A, Pignel R et al. Hyperbaric oxygen therapy promotes wound repair in ischemic and hyperglycemic conditions, increasing tissue perfusion and collagen deposition. Wound Repair Regen. 2016;doi:10.1111/wrr.12480.

60. Frykberg RG, Banks J. Challenges in the treatment of chronic wounds. Adv Wound Care 2015;1:4(9):560-82

61. Health Care Ontario. Hyperbaric oxygen therapy for non-healing ulcers in diabetes mellitus. An evidence-based analysis. Ont Health Technol Assess Ser 2005;5(11):1-28

62. HadI HA, Smerdon G, Fox SW. Osteoclastic resorptive capacity is suppressed in patients receiving hyperbaric oxygen therapy. Acta Orthop 2015;86(2):264-9

63. Tilakaratne A, Soory M. Antioxidant response of osteoblasts to doxycycline in an inflammatory model induced by C-reactive protein and interleukin-6. Infect Disord Drug Targets. 2016;14(1):14-22

64. Keller DC, Carano A. Tetracycline effect on osteoclastic and osteoblastic activity. Gen Dent 1995;43(1):60-3

65. Dunlap T, Keller DC, Marshall et al. Subgingival delivery of oral debriding agents: a proof of concept. Intern J of Appl Dent Res. 2011;@@(5):147-58

66. Keller DC, Buechel M. Direct medication delivery modifies the periodontal biofilm. Oral Biol and Dent. 2017;5(a),www.hoaonline.com

67. Keller DC, Buechel M. Periodontal treatment with direct medication delivery of hydrogen peroxide and oxygen. Oral Health Case Reports DOI: 0.4172/2471-8726.1000133

68. Leach MR, Rees PJ, Wilmshurst P. Hyperbaric oxygen therapy. BMJ 1998;317(7162):1140-43

69. Farrel S, Barker ML et al. Prevention of lingual calculus formation with daily use of 6% H2O2/2% pyrophosphate whitening strips. J Clin Dent 2009;12(3):75-8